Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (231-240 of 383) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in SequenceJacquie H Chirgwin, Anita Giobbie-Hurder, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2024
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5Javier Cortés, Sara A Hurvitz, Joyce O'Shaughnessy, et al.
Nature Medicine|May 7, 2021
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancerAyse Bassez, Hanne Vos, Laurien Van Dyck, et al.
NPJ Breast Cancer|September 22, 2021
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancerAndrea Gombos, David Venet, Lieveke Ameye, et al.
NPJ Breast Cancer|March 17, 2022
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancerAndrea Gombos, David Venet, Lieveke Ameye, et al.
British Journal of Cancer|June 23, 2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancerHoward A Burris, Arlene Chan, Aditya Bardia, et al.
Breast (Edinburgh, Scotland)|April 26, 2017
The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?Matti Aapro, Michelino De Laurentiis, Dan Rea, et al.
NPJ Breast Cancer|December 5, 2025
Personalized ctDNA detection and genomic profiling in the NeoRHEA StudyAlexandra Stanciu, Elisa Agostinetto, Andreas Papagiannis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2019
Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM StudyAnabel Sanchez-Spitman, Vincent Dezentjé, Jesse Swen, et al.
Clinical Breast Cancer|April 21, 2023
The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort StudyNynke Willers, Patrick Neven, Giuseppe Floris, et al.
Pageof 39

Showing results (231-240 of 383) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2016
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in SequenceJacquie H Chirgwin, Anita Giobbie-Hurder, Alan S Coates, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2024
Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5Javier Cortés, Sara A Hurvitz, Joyce O'Shaughnessy, et al.
Nature Medicine|May 7, 2021
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancerAyse Bassez, Hanne Vos, Laurien Van Dyck, et al.
NPJ Breast Cancer|September 22, 2021
FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancerAndrea Gombos, David Venet, Lieveke Ameye, et al.
NPJ Breast Cancer|March 17, 2022
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancerAndrea Gombos, David Venet, Lieveke Ameye, et al.
British Journal of Cancer|June 23, 2021
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancerHoward A Burris, Arlene Chan, Aditya Bardia, et al.
Breast (Edinburgh, Scotland)|April 26, 2017
The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?Matti Aapro, Michelino De Laurentiis, Dan Rea, et al.
NPJ Breast Cancer|December 5, 2025
Personalized ctDNA detection and genomic profiling in the NeoRHEA StudyAlexandra Stanciu, Elisa Agostinetto, Andreas Papagiannis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2019
Tamoxifen Pharmacogenetics and Metabolism: Results From the Prospective CYPTAM StudyAnabel Sanchez-Spitman, Vincent Dezentjé, Jesse Swen, et al.
Clinical Breast Cancer|April 21, 2023
The Upgrade Risk of B3 Lesions to (Pre)Invasive Breast Cancer After Diagnosis on Core Needle or Vacuum Assisted Biopsy. A Belgian National Cohort StudyNynke Willers, Patrick Neven, Giuseppe Floris, et al.
Pageof 39